AzTrials
AzTrials

Obesity-related Poor Sperm QualityNCT07112248

Effects of Soluble Fiber Supplements on Sperm Quality in Males With Obesity: a Randomized Trial

A study testing inulin in people with Obesity-related Poor Sperm Quality and Gut Microbiota, run by Huazhong University of Science and Technology at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Obesity-related poor sperm quality is a significant public health issue, acting as a major contributor to male infertility. Dietary intervention has emerged as an effective strategy to manage obesity and improve sperm quality. Read more about this study

Who is it for?
Ages 18 to 60 years, men onlyHealthy volunteers can take part
What is being tested?
inulin
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
74 participants
Where
1 siteChina
Study dates
10 Aug 2025to 5 Jan 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Male, aged 18-60 years;
  • Diagnostic criteria for obesity: BMI ≥ 28 kg/m² and body fat percentage ≥ 25%;
  • Semen samples can be collected, and sperm concentration > 0.

Who cannot join

  • Spermatogenic dysfunction caused by non-obesity factors;
  • Severe systemic diseases such as cardiovascular/cerebrovascular, hepatic/renal disorders, malignant tumors, uncontrolled diabetes, or thyroid diseases;
  • Recent usage of medications/supplements affecting spermatogenesis or gut microbiota ;
  • Lifestyle factors potentially impairing sperm quality or severe gastrointestinal disorders;
  • Poor compliance, planned imminent fertility, or history of bariatric surgery/weight-loss medications;
  • Significant dietary changes within the past three months.

Trial locations and contacts

1 site in 1 country.

China1 site
  • Hubei Maternal and Child Health Care Hospital

    Wuhan, Hubei

Other trials in China

About this study

Official title: A Randomized Controlled Trial Investigating the Effects of Soluble Dietary Fiber Supplements on Sperm Quality Parameters in Males With Obesity

Obesity-related poor sperm quality is a significant public health issue, acting as a major contributor to male infertility. Dietary intervention has emerged as an effective strategy to manage obesity and improve sperm quality. Soluble dietary fiber (SDF), an essential nutritional component, plays a crucial role in regulating host health. Notably, insufficient SDF intake has been associated with both obesity and low sperm motility. However, the effect of SDF supplementation on sperm quality in males with obesity remains unclear. Thus, we conducted a randomized, placebo-controlled study to investigate the effect of SDF supplementation on sperm quality in males with obesity.

Being tested
Placebo, inulin

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PlaceboDietary supplement

    Maltodextrin

  • inulinDietary supplement

    Inulin is a kind of soluble dietary fiber.

Study groups in NCT07112248
Study groupRoleWhat they receive
Control groupPlacebo comparator15 g maltodextrin in a sachet once daily for 12 weeks.
Receives: Dietary Supplement: Placebo
Soluble dietary fiber groupExperimental15 g inulin in a sachet once daily for 12 weeks.
Receives: Dietary Supplement: inulin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The sperm quality of obese males

    The sperm quality includes the motility, concentration and morphology of sperm and these parameters are all measured by Computer-Assisted Semen Analysis.

    Measured: Baseline, 4 weeks and 12 weeks.

Secondary outcomes (11)
  1. Changes in the levels of sex hormones

    Changes in the levels of sex hormones, including Follicle-Stimulating Hormone (FSH), Luteinizing Hormone (LH), Estradiol (E2), Progesterone (P), Testosterone (T), and Prolactin (PRL).

    Measured: Baseline, 4 weeks, 12 weeks

  2. Changes in sexual function

    The sexual function will be assessed by Brief Male Sexual Function Questionnaire.

    Measured: Baseline, 4 weeks, 12 weeks

  3. Changes in DNA integrity of sperm

    Changes in the sperm DNA fragmentation index (DFI) will be measured by sperm chromatin structure assay (SCSA).

    Measured: Baseline, 4 weeks, 12 weeks

  4. Changes in the gut microbiota

    Changes in the composition, diversity, and function of gut microbiota in feces will be measured by 16S rRNA gene sequencing.

    Measured: Baseline, 4 weeks, 12 weeks

  5. Changes in the levels of bile acids in plasma

    Changes in the levels of bile acids in plasma will be evaluated by liquid chromatography-mass spectrometry (LC-MS).

    Measured: Baseline, 4 weeks, 12 weeks

  6. Changes in the levels of fasting plasma TC, TG, LDL, and HDL

    Measured: Baseline, 4 weeks, 12 weeks

  7. Change in body weight

    Measured: Baseline, 4 weeks, 12 weeks

  8. Change in BMI

    Measured: Baseline, 4 weeks, 12 weeks

  9. Change in waist-to-hip ratio (WHR)

    Measured: Baseline, 4 weeks, 12 weeks

  10. Change in body fat composition

    Measured: Baseline, 4 weeks, 12 weeks

  11. Change in the levels fasting plasma glucose

    Measured: Baseline, 4 weeks, 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Aug 2025
  2. Study start10 Aug 2025
  3. Primary completion4 Jan 2026
  4. Study completion5 Jan 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
74 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07112248
Sponsor's protocol ID
XXM2025157
Status last verified
May 2026
First submitted
2 Aug 2025
Last updated
18 May 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing inulin in people with Obesity-related Poor Sperm Quality and Gut Microbiota, run by Huazhong University of Science and Technology at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The sperm quality of obese males (time frame: Baseline, 4 weeks and 12 weeks.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in